The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.
This study is seeking for participants who are:
* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older
* Prescribed Prevenar 20 by their physician as per approved product label
All participants in this study will receive Prevenar 20 vaccine.
1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle.
We will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe.
Participants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.

Start Date01 Sep 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06855160

/ Not yet recruitingPhase 3

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

Start Date21 Apr 2025

Sponsor / Collaborator

GSK Plc

NCT06806137

/ Not yet recruitingPhase 3

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.

Start Date05 Mar 2025

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

100 Translational Medicine associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

100 Patents (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

2,243

Literatures (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

31 Dec 2025·Human Vaccines & Immunotherapeutics

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis

Article

Author: Vinand, Elizabeth ; Torres, Gustavo Ivan ; Huang, Liping ; Ta, An ; Wannaadisai, Warisa ; Huerta, José Luis

The introduction of a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) into the Mexican pediatric national immunization program (NIP) has substantially reduced the burden of pneumococcal disease (PD) since 2010. This study aimed to estimate the impact of replacing either PCV13 or 15valent PCV (PCV15) with 20-valent PCV (PCV20) in the Mexican pediatric NIP. A decision-analytic Markov model was developed to compare the cost-effectiveness of PCV20 versus lower-valent vaccines from a Mexican public health sector (payer) perspective over 10 years. Epidemiological and cost inputs were sourced from Mexican data. Direct and indirect vaccine effects were estimated using PCV13 clinical effectiveness, 7-valent PCV efficacy studies, and PCV13 impact data in Mexico. The estimated disease and cost impact of PCV20 was compared with PCV13 and PCV15, all under a 2 + 1 dosing schedule. A discount rate of 5% per annum was applied to costs and health outcomes. Model robustness was evaluated through sensitivity analyses, including deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and additional scenario assessments. PCV20 was estimated to provide considerably more health benefits than both comparators by averting more cases of PD compared with both PCV13 and PCV15, as well as a total cost saving of over 10 billion Mexican pesos. The DSA, PSA, and scenario assessments confirmed minimal deviation from the base case. Therefore, the introduction of PCV20 (2 + 1) into the Mexican pediatric NIP is expected to reduce the burden of PD and medical costs compared with lower-valent alternatives.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Global distribution and characteristics of pneumococcal serotypes in adults

Review

Author: Morimoto, Konosuke ; Maeda, Haruka

The introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIP) has significantly reduced invasive pneumococcal diseases and pneumococcal pneumonia caused by PCV serotypes in adults due to herd immunity. However, diseases caused by PCV13 serotypes persist, mainly serotype 3, known for its severity. With the reduction in PCV13 serotypes, diseases caused by non-PCV13 serotypes increased. Residual and emerging serotypes vary regionally; serotype 8 in Europe and South Africa, and serotype 4 in the US and Canada. PCV20 and PCV21 were recently developed, which can prevent residual and emerging pneumococcal diseases where herd immunity is well-established. In countries that have not introduced PCV into pediatric NIP, the pneumococcal disease burden due to PCV serotypes is still marked. Given that serotype distribution varies by region and evolves over time, this review aimed to discuss serotype distribution and disease severity in adults across countries to support future pneumococcal vaccine strategies.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach

Article

Author: Cassell, Kelsie ; Owusu-Edusei, Kwame ; Mueller, Peter P. ; Johnson, Kelly D. ; Tajima, Atsushi ; Cossrow, Nicole ; Yi, Zinan ; Matsuki, Taizo

INTRODUCTION:

This study analyzed the health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) and the 20-valent pneumococcal conjugate vaccine (PCV20), as well as their relative cost-effectiveness, in Japanese adults aged 65 years using a delta pricing approach.

METHODS:

A Markov model was employed to simulate the movement of the Japanese population among four health states: healthy, pneumococcal disease (consisting of invasive pneumococcal disease [IPD] with or without meningitis and non-bacteremic pneumococcal pneumonia [NBPP]), post-meningitis sequelae, and death. The model was populated with publicly available demographic and epidemiologic data, stratified by risk level. Pneumococcal serotype distribution and vaccine effectiveness, as well as direct and indirect treatment costs and health-related utilities, were derived from published sources. The model used a lifetime horizon and 2% discounting of costs and life-years. Costs were adjusted to 2023 values in Japanese yen (¥). Outcomes were cases and deaths, life-years and quality-adjusted life-years (QALYs), vaccination and treatment costs, and incremental cost-effectiveness ratios. The range over which V116 was cost-saving and cost-effective was determined.

RESULTS:

Compared to PCV20, V116 averted an additional 28 cases of IPD, 918 cases of NBPP, 5 deaths from IPD, and 51 deaths from NBPP over the lifetime of a single age 65 cohort. Life-years and QALYs gained were 1,019 and 642, respectively, relative to PCV20; V116 saved ¥733 million in direct medical costs and ¥557 million in indirect costs, compared to PCV20. V116 was found to be cost-saving at price premiums up to ¥1,322 (payer perspective) or ¥2,327 (societal perspective) and remained below a willingness-to-pay threshold of ¥5 million/QALY for premiums up to ¥7,113 (payer perspective) or ¥8,117 (societal perspective).

CONCLUSIONS:

V116 is projected to provide more population health benefits in Japan than PCV20, and to be cost-effective at a variety of price premiums.

107

News (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

28 Mar 2025

·pmlive.com

Merck granted EC approval for adult-specific pneumococcal vaccine Capvaxive

Merck & Co – known as MSD outside the US and Canada – has announced that its adult-specific 21-valent pneumococcal conjugate vaccine has been approved by the European Commission (EC). The vaccine, marketed under the brand name Capvaxive, has been authorised to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 years and older. Invasive pneumococcal disease, including pneumonia, sepsis and meningitis, are major causes of mortality worldwide. There are more than 100 different types of pneumococcal bacteria and Merck’s Capvaxive, which is administered in a single dose, is designed to help protect against the ones that are responsible for the majority of adult invasive pneumococcal disease. The EC’s approval follows a recent recommendation from the European Medicines Agency’s human medicines committee and was based on positive results from the phase 3 STRIDE-3 trial, which compared Capvaxive to Pfizer’s 20-valent vaccine (PCV20) in adults who had not previously received a pneumococcal vaccine. Capvaxive was shown to induce non-inferior immune responses compared to PCV20 for all ten serotypes common to both vaccines in adults aged 50 years and older, and generated superior immune responses for ten of its 11 unique serotypes. Additionally, Merck’s vaccine elicited non-inferior immune responses in adults aged 18 to 49 years compared to those aged 50 to 64 years and had a safety profile comparable to PCV20. Results from the phase 3 STRIDE-4, STRIDE-5, STRIDE-6, STRIDE-7 and STRIDE-10 trials also supported the EU regulator’s decision. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development at Merck Research Laboratories, said: “By focusing on the serotypes that have been responsible for an increasing proportion of adult invasive pneumococcal disease cases, Capvaxive allows us to offer protection specifically designed for adults. “We are proud to bring Capvaxive to adults in Europe who may benefit from its broad protection and are eager to continue working with regulatory authorities to expand Capvaxive availability worldwide.” The authorisation follows the US Food and Drug Administration’s approval of Capvaxive in June last year. The vaccine is also already approved in Canada and Australia.

Drug ApprovalPhase 3Clinical ResultVaccine

27 Mar 2025

·www.pharmaceutical-technology.com

EC approves MSD’s pneumococcal 21-valent conjugate Capvaxive

The availability of MSD’s vaccine in individual nations will be subject to various factors. Credit: Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. MSD has received approval from the European Commission (EC) for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease and pneumonia due to Streptococcus pneumoniae serotypes in people aged 18 years and over. The approval of Capvaxive, indicated for active immunisation, marks a step forward in protection from serotypes most commonly associated with invasive pneumococcal disease (IPD). The EC’s decision allows for the marketing of the vaccine across all 27 European Union member states, along with Liechtenstein, Norway and Iceland. The vaccine’s availability in individual nations will be subject to various factors, including reimbursement procedure completion. In June and July 2024, the vaccine gained approval in the US and Canada. It was approved in Australia in January 2025. The EC’s decision was influenced by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use’s positive recommendation in January 2025. Capvaxive’s approval was supported by the data, which includes Phase III clinical trials to assess its immunogenicity and safety in adults. The pivotal Phase III STRIDE-3 trial was one of the key studies, comparing the vaccine against PCV20 in adults who had not previously received a pneumococcal vaccine. The STRIDE-10 trial compared the vaccine to pneumococcal vaccine, polyvalent [23-valent] (PPSV23) in those aged 50 years and above. The approval was further supported by outcomes from the Phase III STRIDE-4, STRIDE-5, STRIDE-6 and STRIDE-7 trials. The vaccine is administered as a single dose. MSD Research Laboratories Global Clinical Development infectious diseases and vaccines senior vice-president Dr Paula Annunziato stated: “By focusing on the serotypes that have been responsible for an increasing proportion of adult invasive pneumococcal disease cases, Capvaxive allows us to offer protection specifically designed for adults. “We are proud to bring Capvaxive to adults in Europe who may benefit from its broad protection and are eager to continue working with regulatory authorities to expand Capvaxive availability worldwide.” The development follows MSD’s exclusive licence agreement with Jiangsu Hengrui Pharmaceuticals for the investigational oral small molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346.

Drug ApprovalPhase 3License out/inVaccine

26 Mar 2025

·pipelinereview.com

European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults RAHWAY, NJ, USA I March 26, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved CAPVAXIVE ® (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older. CAPVAXIVE is a pneumococcal vaccine specifically designed to help protect adults from the serotypes responsible for the majority of invasive pneumococcal disease (IPD) cases. The EC approval of CAPVAXIVE is based on safety and immunogenicity data from the Phase 3 STRIDE clinical program. This decision authorizes the marketing of CAPVAXIVE in all 27 European Union (EU) member states, as well as Iceland, Liechtenstein and Norway. The timing for availability of CAPVAXIVE in individual countries will depend on multiple factors, including the completion of reimbursement procedures. CAPVAXIVE was approved in the U.S. in June 2024, in Canada in July 2024, and in Australia in January 2025. “Pneumococcal disease continues to pose a significant risk for adults in Europe, among adults who are 65 or older, and also among younger adults who are immunocompromised or have chronic medical conditions,” said Dr. Lina Pérez Breva, Vaccine Research, Fisabio – Public Health, Valencia, Spain. “Based on data from the Phase 3 STRIDE clinical program, CAPVAXIVE offers coverage against the serotypes responsible for the majority of invasive disease cases in adults, making this approval in the EU an important step in helping to protect adults from pneumococcal disease.” “By focusing on the serotypes that have been responsible for an increasing proportion of adult invasive pneumococcal disease cases, CAPVAXIVE allows us to offer protection specifically designed for adults,” said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, Global Clinical Development, Merck Research Laboratories. “We are proud to bring CAPVAXIVE to adults in Europe who may benefit from its broad protection and are eager to continue working with regulatory authorities to expand CAPVAXIVE availability worldwide.” European Union country-level data have demonstrated that the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine), as shown in these selected four countries: Data were included for select countries based on EU membership, population size and the most recent year reported. These values are based on country-level epidemiologic data and regional variations may exist; they do not reflect the efficacy of the respective vaccines. There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20. The decision by the EC follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use released in January 2025 and was based on results from the pivotal Phase 3 STRIDE-3 trial ( NCT05425732 ), which evaluated CAPVAXIVE compared to PCV20 in adults 18 years of age and older who had not previously received a pneumococcal vaccine, and STRIDE-10 ( NCT05569954 ), which compared CAPVAXIVE to PPSV23 (pneumococcal vaccine, polyvalent [23-valent]) in adults 50 years of age and older who had not previously received a pneumococcal vaccine. The approval is also supported by results from the Phase 3 STRIDE-4 ( NCT05464420 ), STRIDE-5 ( NCT05526716 ), STRIDE-6 ( NCT05420961 ), and STRIDE-7 ( NCT05393037 ) trials (see “Clinical data supporting EC approval” below, for additional details). Clinical data supporting EC approval CAPVAXIVE was approved by the EC based on data that included Phase 3 clinical studies designed to evaluate its safety and immunogenicity in a variety of adult populations. These included: About CAPVAXIVE CAPVAXIVE is Merck’s FDA-approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older. CAPVAXIVE is specifically designed to help address Streptococcus pneumoniae serotypes predominantly responsible for adult invasive pneumococcal disease (IPD), including eight unique serotypes, 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B compared to other pneumococcal vaccines. CAPVAXIVE is administered as a single dose. CAPVAXIVE Indication in the U.S. CAPVAXIVE is indicated in the U.S. for: CAPVAXIVE should not be administered to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid; see additional Select Safety Information below. The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Selected Safety Information for CAPVAXIVE in the U.S. Do not administer CAPVAXIVE to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid. Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE. The most commonly reported (>10%) solicited adverse reactions in individuals 18 through 49 years of age who received CAPVAXIVE were: injection-site pain (73.1%), fatigue (36.0%), headache (27.5%), myalgia (16.4%), injection-site erythema (13.8%), and injection-site swelling (13.3%). The most commonly reported (>10%) solicited adverse reactions in individuals 50 years of age and older who received CAPVAXIVE were: injection-site pain (41.2%), fatigue (19.7%), and headache (11.0%). Vaccination with CAPVAXIVE may not protect all vaccine recipients. About pneumococcal disease Pneumococcal disease is an infection caused by a bacteria called Streptococcus pneumoniae . There are about 100 different types (referred to as serotypes) of pneumococcal bacteria, which can affect adults differently than children. Pneumococcal disease can be invasive or non-invasive. Non-invasive pneumococcal illnesses include pneumonia (when pneumococcal disease is confined to the lungs), whereas invasive pneumococcal illnesses include pneumococcal bacteremia (infection in the bloodstream), bacteremic pneumococcal pneumonia (pneumonia with bacteremia) and pneumococcal meningitis (infection of the coverings of the brain and spinal cord). Pneumococcal pneumonia is a type of bacterial pneumonia, which is the most common clinical presentation of pneumococcal disease in adults. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter) , Facebook , Instagram , YouTube and LinkedIn . SOURCE: Merck

Drug ApprovalPhase 3VaccineAccelerated ApprovalClinical Result

100 Deals associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AL	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
invasive Streptococcus pneumoniae infection	South Korea	Pfizer Pharmaceuticals Korea Ltd.	31 Oct 2024
Otitis Media	United States	Wyeth Pharmaceuticals LLC	27 Apr 2023
Pneumococcal Infections	Canada	Pfizer Canada ULC	09 May 2022
Pneumonia, Pneumococcal	European Union	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Iceland	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Liechtenstein	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Norway	Pfizer Europe MA EEIG	14 Feb 2022
Invasive streptococcal disease	United States	Wyeth Pharmaceuticals LLC	08 Jun 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	NDA/BLA	European Union	Pfizer Europe MA EEIG	26 Jan 2024
Respiratory Syncytial Virus Infections	NDA/BLA	United States	Pfizer Inc.	17 May 2023
COVID-19	Phase 3	United States	Pfizer Inc.	20 May 2021
Influenza, Human	Phase 3	United States	Pfizer Inc.	01 Sep 2020
Infectious Lung Disorder	Phase 2	United States	Pfizer Inc.	05 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05886777 (CTgov)	Phase 2	COVID-19 \| Infectious Lung Disorder	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	faiochngin = pptuddbusn uxvlzpobqw (nuahoedxph, jfkghwscef - fywmpknnmm) View more	-	18 Dec 2024
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	faiochngin = ufoqxihrxt uxvlzpobqw (nuahoedxph, teqcylkbvp - cwvxpmcwmd) View more
NCT05875727 (CTgov)	Phase 3	Pneumococcal Infections	405	Pneumococcal vaccine (Cohort 1: 18 to 49 Years)	cekawraton = gixwpdohvx rksnekbkda (jqxnfqyjuc, orengjtegp - wvirdcbmrl) View more	-	24 Oct 2024
				20vPnC vaccine (Cohort 2: >= 50 Years)	cekawraton = csmqglteqi rksnekbkda (jqxnfqyjuc, jpxcadhhcp - qbcvbijbws) View more
NCT05408429 (CTgov)	Phase 3	Pneumococcal Infections	356	20vPnC (2-Dose 20vPnC)	ayptehyslv = loudztadyb feabprlhyn (eyonjcknvj, yekeckqtzd - pgkeiidicl) View more	-	19 Sep 2024
				20vPnC (1-Dose 20vPnC)	ayptehyslv = ryjrsvvndd feabprlhyn (eyonjcknvj, dwaigfrkfl - njubqndgvx) View more
NCT04382326 (CTgov)	Phase 3	Pneumococcal Infections	1,997	20-valent Pneumococcal Conjugate Vaccine (20vPnC) (20vPnC)	fidmhjtnfs = eymjxtfeoo rubdlhrxim (qscpeyycxf, fqyumbtryt - oydbboaemb) View more	-	06 Dec 2023
				13-valent Pneumococcal Conjugate Vaccine (13vPnC) (13vPnC)	fidmhjtnfs = flltczsuvc rubdlhrxim (qscpeyycxf, ulbxlqbkzj - eimabmdebt) View more
NCT04379713 (CTgov)	Phase 3	Pneumococcal Infections	1,511	20vPnC (20vPnC)	bovhbzmjqz = apcnxehwey lcxgghkjcq (eqoadecxbp, bmtslhduwg - didxbhsurd) View more	-	13 Jun 2023
				13vPnC (13vPnC)	bovhbzmjqz = boulbombxe lcxgghkjcq (eqoadecxbp, wzkhgbvwic - mbaevyqwuq) View more
NCT04642079 (CTgov)	Phase 3	Pneumococcal Infections	839	20vPnC+13vPnC (Cohort 1: 20vPnC: >=15 to <24 Months)	mgfisshfgn = fltkdzcsrq mjrovbkyjr (ekpiafssoj, gqzknezefj - gppojxuugk) View more	-	26 Apr 2023
				20vPnC+13vPnC (Cohort 2: 20vPnC: >=2 to <5 Years)	mgfisshfgn = lkdvuxnjfn mjrovbkyjr (ekpiafssoj, gsmmalebbb - kghhkdbyta) View more
NCT04530838 (CTgov)	Phase 3	Pneumococcal Infections	668	20vPnC (20vPnC (SC))	mmhpkhckgz = cyxggvlbmg tghekxplxy (brjudgydxb, pojajxhtlx - ijscfaisvg) View more	-	21 Apr 2023
				13vPnC (13vPnC (SC))	mmhpkhckgz = yadfzvgofi tghekxplxy (brjudgydxb, blvtcaobbk - olfgeymgjz) View more
NCT04887948 (CTgov)	Phase 3	COVID-19 \| Pneumococcal Infections	570	BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site)	txsobwzmix = wcgxujaqbv qfajavydyx (nbeospmaaw, rnslvmmypa - bcrkwuesie) View more	-	14 Dec 2022
				BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site)	txsobwzmix = frihyqqbtx qfajavydyx (nbeospmaaw, tlrvliklyi - nufpyoafvy) View more
NCT04546425 (Corporate Publications) Manual	Phase 3	Pneumococcal Infections	-	20-Valent Pneumococcal Conjugate Vaccine	dpecvivbri(hwrgoypzwb) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated eloctidhwe (cnvbhhwqew )	Non-inferior	19 Sep 2022
				Prevenar 13
NCT04382326 (Corporate Publications) Manual	Phase 3	IRAK4 Deficiency	-	20-Valent Pneumococcal Conjugate Vaccine	tyvagdflrh(aeqclnmiht) = A similar percentage of infants receiving either vaccine experienced local reactions (pain at the injection site, redness, and swelling), fever, and other systemic events (decreased appetite, drowsiness, and irritability) hxuobsdvum (ylubqwsijx )	Non-inferior	12 Aug 2022
				Pneumococcal polysaccharide conjugate vaccine

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis